Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia
Ghobrial, Irene M., Witzig, Thomas E., Gertz, Morie, LaPlant, Betsy, Hayman, Suzanne, Camoriano, John, Lacy, Martha, Bergsagel, P. Leif, Chuma, Stacey, DeAngelo, Daniel, Treon, Steven P.Volume:
89
Langue:
english
Journal:
American Journal of Hematology
DOI:
10.1002/ajh.23620
Date:
March, 2014
Fichier:
PDF, 471 KB
english, 2014